Ensysce Biosciences Income Statement (2017-2025) | ENSCW

Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
0.25M0.44M1.20M1.64M0.60M0.21M0.28M1.43M0.79M0.49M0.44M0.52M0.31M0.18M3.42M1.30M1.32M1.37M0.49M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)
0.28M0.46M1.71M2.19M3.14M5.31M4.76M6.44M1.80M1.64M1.91M2.23M0.78M0.95M1.69M3.80M1.89M1.92M2.95M
Selling, General & Administrative (Quarter)
0.49M0.39M16.37M1.45M2.27M1.95M1.69M1.19M1.55M1.14M1.23M1.44M1.37M1.19M1.08M1.08M1.40M1.20M1.28M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
0.77M0.86M18.09M3.64M5.41M7.26M6.44M7.63M3.35M2.78M3.14M3.67M2.15M2.14M2.77M4.88M3.29M3.12M4.23M
Operating Income (Quarter)
-0.52M-0.41M-16.89M-2.01M-4.80M-7.06M-6.16M-6.20M-2.56M-2.29M-2.71M-3.16M-1.84M-1.96M0.64M-3.58M-1.97M-1.75M-3.74M
EBIT (Quarter)
-0.52M-0.41M-16.89M-2.01M-4.80M-7.06M-6.16M-6.20M-2.56M-2.29M-2.71M-3.16M-1.84M-1.96M0.64M-3.58M-1.97M-1.75M-3.74M
Non-operating items
Interest & Investment Income (Quarter)
229.00
Other Non Operating Income (Quarter)
-0.04M0.71M0.06M-0.06M0.01M0.00M0.01M0.07M0.01M0.01M0.01M-0.01M-0.03M0.01M0.01M0.03M0.02M0.02M0.02M
Non Operating Income (Quarter)
-0.39M-0.35M0.99M-0.34M3.85M-0.87M0.01M0.07M0.01M0.05M0.01M-0.01M-1.27M0.01M0.02M-1.24M0.02M0.02M0.02M
Net income details
EBT (Quarter)
-1.77M-1.32M-16.91M-2.02M-4.82M-7.09M-6.17M-6.20M-2.56M-2.29M-2.71M-3.50M-3.09M-1.98M0.64M-3.58M-1.97M-1.75M-3.75M
Tax Provisions (Quarter)
-0.06M
Profit After Tax (Quarter)
-0.91M-0.96M-17.20M-10.04M-0.95M-7.92M-9.86M-5.48M-2.19M-2.24M-2.69M-3.50M-3.12M-1.97M0.66M-3.56M-1.95M-1.73M-3.73M
Income from Non-Controlling Interests (Quarter)
-0.00M-0.02M-0.04M-214.00182.00-0.03M-0.02M0.01M-0.00M-0.01M-0.00M-965.00-74.00-166.00
Income from Continuing Operations (Quarter)
-1.71M-1.32M-16.91M-2.02M-4.82M-7.09M-6.17M-6.20M-2.56M-2.29M-2.71M-3.50M-3.09M-1.98M0.64M-3.58M-1.97M-1.75M-3.75M
Consolidated Net Income (Quarter)
-1.71M-1.32M-16.91M-2.02M-4.82M-7.09M-6.17M-6.20M-2.56M-2.29M-2.71M-3.50M-3.09M-1.98M0.64M-3.58M-1.97M-1.75M-3.75M
Income towards Parent Company (Quarter)
-1.71M-1.32M-16.91M-2.02M-4.82M-7.09M-6.17M-6.20M-2.56M-2.29M-2.71M-3.50M-3.09M-1.98M0.64M-3.58M-1.97M-1.75M-3.75M
Preferred Dividend Payments (Quarter)
0.72M0.10M0.06M0.03M0.01M0.00M899.00290.00
Net Income towards Common Stockholders (Quarter)
-0.91M-0.94M-17.16M-10.84M-1.67M-8.00M-9.90M-5.52M-2.20M-2.24M-2.69M-3.50M-3.12M-1.97M0.66M-3.56M-1.95M-1.73M-3.73M
Additional items
EPS (Basic) (Quarter)
-0.06-0.06-14.15-9.33-14.66-56.49-61.581.48-2.08-0.98-0.87-67.08-8.21-3.351.00-2.93-1.39-0.79-1.29-0.56
EPS (Weighted Average and Diluted) (Quarter)
-0.71-0.46-56.49-61.581.48-2.08-0.98-0.87-67.08-8.21-3.351.00-2.93-1.39-0.79-1.29-0.56
Shares Outstanding (Weighted Average) (Quarter)
15.83M16.05M0.94M1.01M0.11M0.14M1.67M0.18M1.05M0.42M2.15M0.15M0.38M0.59M0.52M0.70M1.40M2.20M2.89M2.56M
Shares Outstanding (Diluted Average) (Quarter)
18.76M20.16M0.13M0.14M0.18M1.05M2.27M3.09M0.15M0.38M0.59M0.66M0.70M1.40M2.20M2.89M2.56M
EBITDA (Quarter)
-0.52M-0.41M-16.89M-2.01M-4.80M-7.06M-6.16M-6.20M-2.56M-2.29M-2.71M-3.16M-1.84M-1.96M0.64M-3.58M-1.97M-1.75M-3.74M
Interest Expenses (Quarter)
0.35M0.91M0.02M0.01M0.02M0.04M0.00M0.00M0.00M0.01M0.34M1.25M0.03M0.00M0.00M0.00M0.00M0.01M-992.00
Tax Rate (Quarter)
3.46%